

()
// , ,
//

*

, :

:

PH

Infant star 500

/

%

F102

% , (%) % (%) % :
() % () %
 , () %
:

NICU

:

Avery

Fujiwara . ()

() (RDS)

, , , ,

. ()

/ PH

Infant star 500

 FiO_2

. (-) RDS

. ()

()

()

. ()

RDS

NICU

(%)

(%)

(%)

(%)

-

()

NICU

(%)

(%)

(%)

—

—

therapy)

(PIE)

%

% %

PIE

PIE % /

()Navas

% /

)

(

(% /)

%

%

% ()

REFERENCES

1. Avery ME, Mead J. Surface Properties in relation to atelectasis and hyalin membrane disease. *Am J Dis Child* 1959; 97 : 517-23.
2. Shapiro DL. Future of surfactant replacement therapy. In: Shapiro DL, Notter RH, eds. New york , Ny : Alan R. Liss Inc. 1989. pp:305-9.
3. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyalin membrane disease . *Lancet* 1980;1(8159):55-9.
4. Halliday HL. Natural VS synthetic Surfactant in neonatal respiratory distress Syndrome. *Drugs* 1996;51(2):226-37.
5. Robertson B, Halliday HL. Principles of surfactant replacement. *Biochim Biophys Acta* 1998;1408(2-3):346-61.
6. Soll RF. Synthetic Surfactant for respiratory distress Syndrome in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester: John Wiley & Sons, LTd.
7. Verhagen AA, Keli SO, van der Meulen GN, Wiersma H, Arias M, Angelista IR, et al. Surfactant treatment in premature infants with respiratory distress syndrome in Curacao. *West Indian Med J*;50(2):117-22.
8. Görbe E, Jeager J, Kohalmi B, Patkós P, Cziniel M, Sassi L.. The Combine effect of prenatal steroid prophylaxis, neonatal Surfactant therapy and reduction of risk of complication from infants. *Orv Hetil* 2004;145(23):1227-32.
9. Genzel-Boroviczény O, MacWilliams S, Von Poblitzki M, Zoppelli L. Mortality and major morbidity in premature infants less than 31 weeks gestational age in the decade after introduction of surfactant. *Acta Obstet Gynecol Sand* 2006 ; 85(1) : 68-73.
10. American Academy of pediatrics committee of Fetus and Newborn. Surfactant replacement therapy for respiratory distress Syndrome. *Pediatrics* 1991;87:946-7.
11. Jobe AH. Pulmonary Surfactant therapy. *N Engl J Med* 1993 :328(12):861-8.
12. Bancalari E, del Moral T. Bronchopulmonary dysplasia and Surfactant. *Biol Neonate* 2001;80 suppl 1:7 -13.
13. Raju TNK, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a Meta analysis. *J Pediatr Res* 1993;123:603-10.
14. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al. High frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. *N Engl J Med* 2002;347(9):633-42.
15. Kendig JW, Ryan RM, Sinkin RA, Maniscalco WM, Notter RH, Guillet R, et al. Comparision of two strategies for Surfactant prophylaxis in very premature infants: A multicanter randomized trial. *Pediatrics* 1998; 101(6):1006-12.

-
- / ,
16. Gortner L, Wauer RR, Hammer H, Stock GJ, Heitmann F, Reiter HL, et al. Early versus late Surfactant treatment in preterm infants of 27 to 32 weeks Gestational age: A Multicenter Controlled Clinical Trial. *Pediatrics* 1998;102(5):1153-9.
 17. Navas Serrano VM, Cuevas García MA, Vila Alvarez JA, Martínez Fernández V, Morcillo Sopena F, Valls I Soler A. Prophylaxis and Treatment of respiratory distress Syndrome with different surfactant. *An Esp Pediatr* 2002;56(1):40-4.
 18. Verhagen AA, van der Meulen GN, Wiersma HE, Keli SO, Angelista IR, Muskiet FD, et al. Respiratory distress Syndrome in curacao. Conventional versus surfactant treatment . *West Indian Med J* 2002;51(2):68-73.
 19. Lamboley-Gilmert G, Lacaze Masmonteil T, Neonatologists of the curosurf post marketing French study. The short term out come of a large cohort of very preterm infants treated with poractant alfa (curosurf) for respiratory distress syndrome. A Postmarketing phase IV study. *Paediatr Drugs* 2003;5(9):639-45.